Nasus Pharma Ltd.
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency… Read more
Nasus Pharma Ltd. (NSRX) - Total Assets
Latest total assets as of December 2024: $717.00K USD
Based on the latest financial reports, Nasus Pharma Ltd. (NSRX) holds total assets worth $717.00K USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nasus Pharma Ltd. - Total Assets Trend (2022–2024)
This chart illustrates how Nasus Pharma Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nasus Pharma Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Nasus Pharma Ltd.'s total assets of $717.00K consist of 63.7% current assets and 36.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Nasus Pharma Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nasus Pharma Ltd.'s current assets represent 63.7% of total assets in 2024, a decrease from 100.0% in 2022.
- Cash Position: Cash and equivalents constituted 39.6% of total assets in 2024, up from 36.9% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Nasus Pharma Ltd. Competitors by Total Assets
Key competitors of Nasus Pharma Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Nasus Pharma Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Nasus Pharma Ltd. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nasus Pharma Ltd. is currently not profitable relative to its asset base.
Nasus Pharma Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.12 | 0.10 | 0.10 |
| Quick Ratio | 0.12 | 0.10 | 0.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.47 Million | $ -3.80 Million | $ -3.80 Million |
Nasus Pharma Ltd. - Advanced Valuation Insights
This section examines the relationship between Nasus Pharma Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 16.82 |
| Asset Growth Rate (YoY) | 61.5% |
| Total Assets | $717.00K |
| Market Capitalization | $12.06 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nasus Pharma Ltd.'s assets at a significant premium ( 16.82x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Nasus Pharma Ltd.'s assets grew by 61.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nasus Pharma Ltd. (2022–2024)
The table below shows the annual total assets of Nasus Pharma Ltd. from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $717.00K | +61.49% |
| 2023-12-31 | $444.00K | +6.47% |
| 2022-12-31 | $417.00K | -- |